IL2 and myelodysplastic syndrome: This therapy regimen has been used successfully in PML in Hodgkin’s lymphoma and myelodysplastic syndrome.15,47 In 2016, Dubey et al. described IL2 treatment in a natalizumab-associated PML.48 Evidence, though, is still lacking particularly with respect to long-term responses.